FundedIQ

Funded Startups in West Lafayette

West Lafayette’s newest activity spans from 2022-02-10 (AnalySwift, Grant, $100K) through 2025-10-17 (Neurava, Venture, $2M), with the latest disclosed rou…

West Lafayette’s newest activity spans from 2022-02-10 (AnalySwift, Grant, $100K) through 2025-10-17 (Neurava, Venture, $2M), with the latest disclosed round on 2025-10-17. Most disclosed amounts cluster in the roughly $1M–$15M range, but Eradivir’s $10M (2024-09-23) and Vibronix’s $14M (2024-06-24) sit well above the rest; the only disclosed round above $10M is Vibronix’s $14M. Sector concentration is notable: Biotechnology appears in 4 of 12 entries (Adipo Therapeutics at $5M on 2024-12-11; Amplified Sciences at $3M on 2024-11-25; NutraMaize at $460K on 2024-01-09; MorphImmune at $15M on 2023-05-16), and multiple rounds land in a tight 2024 window (June–December 2024 contains 6 of the 12 rows).

On stage signaling, “Series Unknown” appears 5 times and “undisclosed” appears once (Blue Wave AI Labs, 2023-06-10), making disclosed comparisons uneven across time and rounds. An outlier in visibility is Blue Wave AI Labs: despite being an AI entry in 2023-06-10, its round is undisclosed, whereas the smallest disclosed amount is AnalySwift’s $100K on 2022-02-10.

Most recent rounds

12 shown

Related listings

Frequently asked

What stands out in round size, and is there a clear gap between the largest disclosed round and the rest?

The largest disclosed amount is MorphImmune’s $15M (2023-05-16). That level is well above the next-largest disclosed rounds of Vibronix’s $14M (2024-06-24) and Eradivir’s $10M (2024-09-23), while several other rounds sit at $5M or below (e.g., Wavelogix $1M on 2024-10-02; NutraMaize $460K on 2024-01-09).

Do the most recent rounds cluster in a narrow time window, or are they spread out evenly across years?

They cluster in 2024: 6 of the 12 rows fall between 2024-06-24 (Vibronix) and 2024-12-11 (Adipo Therapeutics). Earlier activity appears in 2022–2023 (e.g., AnalySwift $100K on 2022-02-10; MorphImmune $15M on 2023-05-16), but the density is clearly higher in late 2024.

Which sectors appear most often, and does the list skew toward any one category?

Biotechnology is the most repeated sector at 4 of 12 entries (Adipo Therapeutics $5M on 2024-12-11; Amplified Sciences $3M on 2024-11-25; NutraMaize $460K on 2024-01-09; MorphImmune $15M on 2023-05-16). Health Care accounts for 3 entries (Neurava $2M on 2025-10-17; Vibronix $14M on 2024-06-24; Vasc-Alert $160K on 2022-12-07), while AI shows up once (Blue Wave AI Labs, 2023-06-10, undisclosed).

How much of the dataset has missing or non-comparable round-size signals due to “Series Unknown” or undisclosed amounts?

“Series Unknown” appears in 5 of 12 rows (Neurava is Venture - Series Unknown; Adipo Therapeutics; Wavelogix; NutraMaize; Blue Wave AI Labs). Separately, one company has an undisclosed amount: Blue Wave AI Labs (2023-06-10), so its round can’t be compared by disclosed size against entries like Vibronix $14M (2024-06-24) or Eradivir $10M (2024-09-23).

What stage mix dominates, and are the largest disclosed rounds concentrated in a specific stage?

Seed appears 3 times (W3i Software $2M on 2025-03-12; Amplified Sciences $3M on 2024-11-25; Vasc-Alert $160K on 2022-12-07). Series Unknown appears 5 times, which is the largest share, while the biggest disclosed amounts are split across stages: MorphImmune’s $15M is Series Unknown (2023-05-16), Vibronix’s $14M is Series A (2024-06-24), and Eradivir’s $10M is Series A (2024-09-23).

Are there meaningful outliers beyond size, such as unusually small disclosed rounds or missing amounts?

Yes: the smallest disclosed amount is AnalySwift’s $100K (Grant, 2022-02-10), which is far below most other disclosed rounds. Additionally, Blue Wave AI Labs (Artificial Intelligence, 2023-06-10) is an outlier in comparability because its round amount is undisclosed, unlike neighboring biotech and health care entries with disclosed figures.

Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.